Kan Chen

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm).

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm).

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.